Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human CV6-168 with folinic acid and 5-fluorouracil in advanced cancer
ISRCTN12434145Phase 2Recruiting
- Sponsor
- CV6 Therapeutics
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of CV6-168 in advanced cancer and Nonhematologic neoplasms (2 arms), sponsored by CV6 Therapeutics. Primary endpoints: Dose-limiting toxicity or maximum feasible dose, Safety and tolerability and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
CV6-168
03
Conditions
advanced cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN12434145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12434145.